Skip to main content

Articles

Page 21 of 62

  1. Diabetes is associated with a significantly elevated risk of cardiovascular disease and its specific pathophysiology remains unclear. Recent studies have changed our understanding of cardiac cellularity, with ...

    Authors: Charles D. Cohen, Miles J. De Blasio, Man K. S. Lee, Gabriella E. Farrugia, Darnel Prakoso, Crisdion Krstevski, Minh Deo, Daniel G. Donner, Helen Kiriazis, Michelle C. Flynn, Taylah L. Gaynor, Andrew J. Murphy, Grant R. Drummond, Alexander R. Pinto and Rebecca H. Ritchie
    Citation: Cardiovascular Diabetology 2021 20:116
    Content type: Original investigation Published on:

  2. Prior studies in animal models showed that increased cardiac expression of TRIB3 has a pathogenic role in inducing left ventricular mass (LVM). Whether alterations in TRIB3 expression or function have a pathog...

    Authors: Gaia Chiara Mannino, Carolina Averta, Teresa Vanessa Fiorentino, Elena Succurro, Rosangela Spiga, Elettra Mancuso, Sofia Miceli, Maria Perticone, Angela Sciacqua, Francesco Andreozzi and Giorgio Sesti
    Citation: Cardiovascular Diabetology 2021 20:115
    Content type: Original investigation Published on:

  3. Carotid atherosclerosis represents one of the complications of diabetes mellitus. In particular, plaque instability contributes to disease progression and stroke incidence. High mobility group box-1 (HMGB1) is...

    Authors: Federico Biscetti, Giovanni Tinelli, Maria Margherita Rando, Elisabetta Nardella, Andrea Leonardo Cecchini, Flavia Angelini, Giuseppe Straface, Marco Filipponi, Vincenzo Arena, Dario Pitocco, Antonio Gasbarrini, Massimo Massetti and Andrea Flex
    Citation: Cardiovascular Diabetology 2021 20:114
    Content type: Original investigation Published on:

    The Correction to this article has been published in Cardiovascular Diabetology 2021 20:184

  4. Previous studies has shown a significant relationship between baseline triglyceride-glucose (TyG) index and subsequent cardiovascular disease (CVD). However, the effect of longitudinal changes in TyG index on ...

    Authors: Anxin Wang, Xue Tian, Yingting Zuo, Shuohua Chen, Xia Meng, Shouling Wu and Yongjun Wang
    Citation: Cardiovascular Diabetology 2021 20:113
    Content type: Original investigation Published on:

  5. In a recently published paper in Cardiovascular Diabetology, Sinha et al. (Association of fasting glucose with lifetime risk of incident heart failure: the Lifetime Risk Pooling Project. Cardiovasc Diabetol. 2021...

    Authors: Jian-di Wu, Dong-liang Liang and Yue Xie
    Citation: Cardiovascular Diabetology 2021 20:112
    Content type: Commentary Published on:

  6. The metabolic syndrome (MetS), defined by the simultaneous clustering of cardio-metabolic risk factors, is a significant worldwide public health burden with an estimated 25% prevalence worldwide. The pathogene...

    Authors: Mohamed A. Elhadad, Rory Wilson, Shaza B. Zaghlool, Cornelia Huth, Christian Gieger, Harald Grallert, Johannes Graumann, Wolfgang Rathmann, Wolfgang Koenig, Moritz F. Sinner, Kristian Hveem, Karsten Suhre, Barbara Thorand, Christian Jonasson, Melanie Waldenberger and Annette Peters
    Citation: Cardiovascular Diabetology 2021 20:111
    Content type: Original investigation Published on:

  7. Since 1985, the thiazolidinedione pioglitazone has been widely used as an insulin sensitizer drug for type 2 diabetes mellitus (T2DM). Although fluid retention was early recognized as a safety concern, data fr...

    Authors: Lorenzo Nesti, Domenico Tricò, Alessandro Mengozzi and Andrea Natali
    Citation: Cardiovascular Diabetology 2021 20:109
    Content type: Review Published on:

  8. Diabetes mellitus (DM) and depression are bidirectionally interrelated. We recently identified long-term trajectories of depression symptom severity in individuals with coronary heart disease (CHD), which were...

    Authors: Raphael S. Peter, Andrea Jaensch, Ute Mons, Ben Schöttker, Roman Schmucker, Wolfgang Koenig, Hermann Brenner and Dietrich Rothenbacher
    Citation: Cardiovascular Diabetology 2021 20:108
    Content type: Original investigation Published on:

  9. In a recent meta-analysis of randomized controlled trials of sodium glucose co-transporter 2 inhibitors (SGLT2i) in patients with diabetes, Lin and colleagues showed a positive association between SGLT2i-induc...

    Authors: Louis Potier, Kamel Mohammedi, Gilberto Velho and Ronan Roussel
    Citation: Cardiovascular Diabetology 2021 20:107
    Content type: Commentary Published on:

  10. Type 2 diabetes mellitus (DM) is one of the most common comorbidities among patients with heart failure (HF) with reduced ejection fraction (HFrEF). There are limited data regarding efficacy of hybrid comprehe...

    Authors: Renata Główczyńska, Ewa Piotrowicz, Dominika Szalewska, Ryszard Piotrowicz, Ilona Kowalik, Michael J. Pencina, Wojciech Zaręba, Maciej Banach, Piotr Orzechowski, Sławomir Pluta, Robert Irzmański, Zbigniew Kalarus and Grzegorz Opolski
    Citation: Cardiovascular Diabetology 2021 20:106
    Content type: Original investigation Published on:

  11. Metabolic syndrome (MetS) is an independent risk factor for the incidence of cardiovascular diseases. We investigated whether or to what extent MetS and its components was associated with coronary collateraliz...

    Authors: Tong Liu, Zheng Wu, Jinghua Liu, Yun Lv and Wenzheng Li
    Citation: Cardiovascular Diabetology 2021 20:104
    Content type: Original investigation Published on:

  12. Transferring results obtained in cardiovascular outcome trials (CVOTs) to the real-world setting is challenging. We herein transposed CVOT results to the population of patients with type 2 diabetes (T2D) seen ...

    Authors: V. Sciannameo, P. Berchialla, A. Avogaro and G. P. Fadini
    Citation: Cardiovascular Diabetology 2021 20:103
    Content type: Original investigation Published on:

  13. Women with type 2 diabetes are disproportionally affected by macrovascular complications; we here investigated whether this is also the case for microvascular complications and retinal microvascular measures.

    Authors: Rianneke de Ritter, Simone J. S. Sep, Carla J. H. van der Kallen, Marleen M. J. van Greevenbroek, Marit de Jong, Rimke C. Vos, Michiel L. Bots, Jos P. H. Reulen, Alfons J. H. M. Houben, Carroll A. B. Webers, Tos T. J. M. Berendschot, Pieter C. Dagnelie, Simone J. P. M. Eussen, Miranda T. Schram, Annemarie Koster, Sanne A. E. Peters…
    Citation: Cardiovascular Diabetology 2021 20:102
    Content type: Original investigation Published on:

  14. Several studies suggest that, together with glucose variability, the variability of other risk factors, as blood pressure, plasma lipids, heart rate, body weight, and serum uric acid, might play a role in the ...

    Authors: Antonio Ceriello and Francesco Prattichizzo
    Citation: Cardiovascular Diabetology 2021 20:101
    Content type: Review Published on:

  15. Cardiac arrhythmias are associated with poorer outcomes in patients with heart failure (HF), diabetes mellitus (DM), and chronic kidney disease (CKD). Previous studies have shown inconsistent conclusions regar...

    Authors: Hang-Long Li, Gregory Y. H. Lip, Qi Feng, Yue Fei, Yi-Kei Tse, Mei-zhen Wu, Qing-wen Ren, Hung-Fat Tse, Bernard-M. Y. Cheung and Kai-Hang Yiu
    Citation: Cardiovascular Diabetology 2021 20:100
    Content type: Original investigation Published on:

    The Correction to this article has been published in Cardiovascular Diabetology 2021 20:177

  16. About 50% of hospitalized coronavirus disease 2019 (COVID-19) patients with diabetes mellitus (DM) developed myocardial damage. The mechanisms of direct SARS-CoV-2 cardiomyocyte infection include viral invasio...

    Authors: Nunzia D’Onofrio, Lucia Scisciola, Celestino Sardu, Maria Consiglia Trotta, Marisa De Feo, Ciro Maiello, Pasquale Mascolo, Francesco De Micco, Fabrizio Turriziani, Emilia Municinò, Pasquale Monetti, Antonio Lombardi, Maria Gaetana Napolitano, Federica Zito Marino, Andrea Ronchi, Vincenzo Grimaldi…
    Citation: Cardiovascular Diabetology 2021 20:99
    Content type: Original investigation Published on:

  17. Metabolic syndrome certainly favors growth of carotid plaque; however, it is uncertain if it determines plaque destabilization. Furthermore, it is likely that only some components of metabolic syndrome are ass...

    Authors: Francesca Servadei, Lucia Anemona, Marina Cardellini, Manuel Scimeca, Manuela Montanaro, Valentina Rovella, Francesca Di Daniele, Erica Giacobbi, Iacopo Maria Legramante, Annalisa Noce, Rita Bonfiglio, Patrizia Borboni, Nicola Di Daniele, Arnaldo Ippoliti, Massimo Federici and Alessandro Mauriello
    Citation: Cardiovascular Diabetology 2021 20:98
    Content type: Original investigation Published on:

  18. Type 2 Diabetes is a major risk factor for cardiovascular (CV) mortality. Insulin resistance can be evaluated non-invasively by insulin sensitivity indices (ISI) such as the Mcauley index (MCAi), which is a fu...

    Authors: Yonatan Moshkovits, David Rott, Angela Chetrit and Rachel Dankner
    Citation: Cardiovascular Diabetology 2021 20:97
    Content type: Original investigation Published on:

  19. Increased risk of cardiovascular events is associated not only with dyslipidemias, but also with abnormalities in glucose metabolism and liver function. This study uses pooled analysis to explore the in-depth ...

    Authors: Koutaro Yokote, Shizuya Yamashita, Hidenori Arai, Eiichi Araki, Mitsunori Matsushita, Toshiaki Nojima, Hideki Suganami and Shun Ishibashi
    Citation: Cardiovascular Diabetology 2021 20:96
    Content type: Original investigation Published on:

  20. The association between glucose variability and the progression of atherosclerosis is not completely understood. We aimed to evaluate the associations of glucose variability with the progression of atheroscler...

    Authors: Naohiro Taya, Naoto Katakami, Tomoya Mita, Yosuke Okada, Satomi Wakasugi, Hidenori Yoshii, Toshihiko Shiraiwa, Akihito Otsuka, Yutaka Umayahara, Kayoko Ryomoto, Masahiro Hatazaki, Tetsuyuki Yasuda, Tsunehiko Yamamoto, Masahiko Gosho, Iichiro Shimomura and Hirotaka Watada
    Citation: Cardiovascular Diabetology 2021 20:95
    Content type: Original investigation Published on:

  21. Atherogenic dyslipidemia (AD), characterized by increased concentrations of apolipoprotein B (ApoB)-containing particles, is often present in individuals with type 2 diabetes mellitus (T2DM). Non-high-density ...

    Authors: Alberto J. Lorenzatti, Maria Laura Monsalvo, J. Antonio G. López, Huei Wang and Robert S. Rosenson
    Citation: Cardiovascular Diabetology 2021 20:94
    Content type: Original investigation Published on:

  22. Sodium–glucose cotransporter 2 inhibitor (SGLT2i) use reduces body weight (BW) in patients with type 2 diabetes mellitus (T2DM). Obesity and T2DM are strong risk factors of new-onset atrial fibrillation (AF). ...

    Authors: Yi-Hsin Chan, Shao-Wei Chen, Tze-Fan Chao, Yi-Wei Kao, Chien-Ying Huang and Pao-Hsien Chu
    Citation: Cardiovascular Diabetology 2021 20:93
    Content type: Original investigation Published on:

  23. During the last decade we experienced a surge in the number of glucose lowering agents that can be used to treat patients with type 2 diabetes. Especially important are the discoveries that sodium glucose co-t...

    Authors: Ofri Mosenzon, Stefano Del Prato, Meir Schechter, Lawrence A. Leiter, Antonio Ceriello, Ralph A. DeFronzo and Itamar Raz
    Citation: Cardiovascular Diabetology 2021 20:92
    Content type: Review Published on:

  24. To exam the associations between the use of sodium glucose co-transporter 2 inhibitor (SGLT2i) and the risk of lower limb complications, and to analyze the associated factors.

    Authors: Chu Lin, Xingyun Zhu, Xiaoling Cai, Wenjia Yang, Fang Lv, Lin Nie and Linong Ji
    Citation: Cardiovascular Diabetology 2021 20:91
    Content type: Original investigation Published on:

    The Correction to this article has been published in Cardiovascular Diabetology 2021 20:119

  25. Diabetic and obese patients are at higher risk of severe disease and cardiac injury in corona virus 2 (SARS-CoV-2) infections. Cellular entry of SARS-CoV-2 is mainly via the angiotensin-converting enzyme 2 (AC...

    Authors: Michal Herman-Edelstein, Tali Guetta, Amir Barnea, Maayan Waldman, Naomi Ben-Dor, Yaron D. Barac, Ran Kornowski, Michael Arad, Edith Hochhauser and Dan Aravot
    Citation: Cardiovascular Diabetology 2021 20:90
    Content type: Original investigation Published on:

    The Correction to this article has been published in Cardiovascular Diabetology 2021 20:216

  26. The lipid-lowering and positive cardiovascular effect of proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors was shown in several studies, hence, they are more widely used in the lipid-lowering ma...

    Authors: Laurenz T. Fischer, Daniel A. Hochfellner, Lisa Knoll, Tina Pöttler, Julia K. Mader and Felix Aberer
    Citation: Cardiovascular Diabetology 2021 20:89
    Content type: Original investigation Published on:

  27. High blood pressure is a major risk factor for cardiovascular disease. Visit-to-visit blood pressure variability (BPV) has recently been shown to predict cardiovascular outcomes. We investigated the predictive...

    Authors: Yuen-Kwun Wong, Yap-Hang Chan, JoJo S. H. Hai, Kui-Kai Lau and Hung-Fat Tse
    Citation: Cardiovascular Diabetology 2021 20:88
    Content type: Original investigation Published on:

  28. Left ventricular (LV) longitudinal myocardial dysfunction is considered a marker of preclinical LV dysfunction in patients with type 2 diabetes mellitus (T2DM). High heart rate (HR) is associated with cardiova...

    Authors: Yuki Yamauchi, Hidekazu Tanaka, Shun Yokota, Yasuhide Mochizuki, Yuko Yoshigai, Hiroaki Shiraki, Kentaro Yamashita, Yusuke Tanaka, Ayu Shono, Makiko Suzuki, Keiko Sumimoto, Kensuke Matsumoto, Yushi Hirota, Wataru Ogawa and Ken-ichi Hirata
    Citation: Cardiovascular Diabetology 2021 20:87
    Content type: Original investigation Published on:

  29. Chronic kidney disease (CKD) introduces an increased cardiovascular risk among patients with diabetes mellitus (DM). The risk and tempo of cardiovascular diseases may differ depending upon their type. Whether ...

    Authors: Chia-Ter Chao, Szu-Ying Lee, Jui Wang, Kuo-Liong Chien and Kuan-Yu Hung
    Citation: Cardiovascular Diabetology 2021 20:86
    Content type: Original investigation Published on:

  30. To investigate early and long-term outcomes after treatment of carotid artery stenosis in patients with type 2 diabetes (T2D) compared to patients without T2D.

    Authors: Alexander Zabala, Anders Gottsäter, Marcus Lind, Ann-Marie Svensson, Björn Eliasson, Rebecka Bertilsson, Jan Ekelund, Thomas Nyström and Magnus Jonsson
    Citation: Cardiovascular Diabetology 2021 20:85
    Content type: Original investigation Published on:

  31. The prognostic value of N-terminal pro-brain natriuretic peptide (NT-proBNP) in patients with coronary artery disease (CAD) with different glucose status has not been established. This study sought to evaluate...

    Authors: Hui-Hui Liu, Ye-Xuan Cao, Jing-Lu Jin, Yuan-Lin Guo, Cheng-Gang Zhu, Na-Qiong Wu, Ying Gao, Yan Zhang, Rui-Xia Xu, Qian Dong and Jian-Jun Li
    Citation: Cardiovascular Diabetology 2021 20:84
    Content type: Original investigation Published on:

  32. Controlled studies and observational studies have shown that sodium-glucose cotransporter type 2 inhibitors (SGLT-2i) are beneficial for the survival of patients with heart failure (HF). However, it is unclear...

    Authors: Caiyun Zheng, Meimei Lin, Yan Chen, Haiting Xu, Lingqun Yan and Hengfen Dai
    Citation: Cardiovascular Diabetology 2021 20:83
    Content type: Original investigation Published on:

  33. The triglyceride-glucose index (TyG index) has been proposed as a simple and reliable alternative insulin resistance (IR) marker, while the homeostasis model assessment for IR (HOMA-IR) is the most frequently ...

    Authors: Shujie Wang, Juan Shi, Ying Peng, Qianhua Fang, Qian Mu, Weiqiong Gu, Jie Hong, Yifei Zhang and Weiqing Wang
    Citation: Cardiovascular Diabetology 2021 20:82
    Content type: Original investigation Published on:

  34. To analyze incidence, use of therapeutic procedures, and in-hospital outcomes in patients with ST elevation myocardial infarction (STEMI) and non-ST elevation myocardial infarction (NSTEMI) according to the pr...

    Authors: Ana Lopez-de-Andres, Rodrigo Jimenez-Garcia, Valentin Hernández-Barrera, Jose M. de Miguel-Yanes, Romana Albaladejo-Vicente, Rosa Villanueva-Orbaiz, David Carabantes-Alarcon, Jose J. Zamorano-Leon, Marta Lopez-Herranz and Javier de Miguel-Diez
    Citation: Cardiovascular Diabetology 2021 20:81
    Content type: Original investigation Published on:

  35. Cardiac diastolic dysfunction (DD) and arterial stiffness are early manifestations of obesity-associated prediabetes, and both serve as risk factors for the development of heart failure with preserved ejection...

    Authors: Annayya R. Aroor, Srinivas Mummidi, Juan Carlos Lopez-Alvarenga, Nitin Das, Javad Habibi, Guanghong Jia, Guido Lastra, Bysani Chandrasekar and Vincent G. DeMarco
    Citation: Cardiovascular Diabetology 2021 20:80
    Content type: Original investigation Published on:

  36. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Elena M. Yubero-Serrano, Juan F. Alcalá-Diaz, Francisco M. Gutierrez-Mariscal, Antonio P. Arenas-de Larriva, Patricia J. Peña-Orihuela, Ruth Blanco-Rojo, Javier Martinez-Botas, Jose D. Torres-Peña, Pablo Perez-Martinez, Jose M. Ordovas, Javier Delgado-Lista, Diego Gómez-Coronado and Jose Lopez-Miranda
    Citation: Cardiovascular Diabetology 2021 20:79
    Content type: Correction Published on:

    The original article was published in Cardiovascular Diabetology 2021 20:72

  38. Patients with type 2 diabetes (T2DM) have a prothrombotic state that needs to be fully clarified; microparticles (MPs) have emerged as mediators and markers of this condition. Thus, we investigate, in vivo, in...

    Authors: Alessandra Giannella, Giulio Ceolotto, Claudia Maria Radu, Arianna Cattelan, Elisabetta Iori, Andrea Benetti, Fabrizio Fabris, Paolo Simioni, Angelo Avogaro and Saula Vigili de Kreutzenberg
    Citation: Cardiovascular Diabetology 2021 20:77
    Content type: Original investigation Published on:

  39. Insulin resistance has been demonstrated to be involved in the pathogenesis of atherosclerotic cardiovascular diseases (ASCVDs). This study evaluated the association between the triglyceride–glucose (TyG) inde...

    Authors: Xiaobo Ding, Xiaozhen Wang, Jing Wu, Manli Zhang and Meizi Cui
    Citation: Cardiovascular Diabetology 2021 20:76
    Content type: Original investigation Published on:

  40. The 6th Cardiovascular Outcome Trial (CVOT) Summit “Cardiovascular and Renal Outcomes 2020” was the first to be held virtually on October 29–30, 2020. As in previous years, this summit served as reference meet...

    Authors: Oliver Schnell, Xavier Cos, Francesco Cosentino, Thomas Forst, Francesco Giorgino, Hiddo J. L. Heersprink, Mikhail Kosiborod, Christoph Wanner and Eberhard Standl
    Citation: Cardiovascular Diabetology 2021 20:75
    Content type: Commentary Published on:

  41. The glucose-lowering independent effect of sodium glucose cotransporter-2 inhibitors (SGLT2i) on arterial wall function has not yet been clarified. This study aims to assess whether SGLT2i treatment can attenu...

    Authors: Andrei C. Sposito, Ikaro Breder, Alexandre A. S. Soares, Sheila T. Kimura-Medorima, Daniel B. Munhoz, Riobaldo M. R. Cintra, Isabella Bonilha, Daniela C. Oliveira, Jessica Cunha Breder, Pamela Cavalcante, Camila Moreira, Filipe A. Moura, Jose Carlos de Lima-Junior, Helison R. P. do Carmo, Joaquim Barreto, Wilson Nadruz…
    Citation: Cardiovascular Diabetology 2021 20:74
    Content type: Original investigation Published on:

  42. Essential hypertension and type 2 diabetes mellitus (T2DM) are two common chronic diseases that often coexist, and both of these diseases can cause heart damage. However, the additive effects of essential hype...

    Authors: Wei-feng Yan, Yue Gao, Yi Zhang, Ying-kun Guo, Jin Wang, Li Jiang, Yuan Li and Zhi-gang Yang
    Citation: Cardiovascular Diabetology 2021 20:73
    Content type: Original investigation Published on:

  43. Peripheral artery disease (PAD) is recognized as a significant predictor of mortality and adverse cardiovascular outcomes in patients with coronary heart disease (CHD). In fact, coexisting PAD and CHD is stron...

    Authors: Elena M. Yubero-Serrano, Juan F. Alcalá-Diaz, Francisco M. Gutierrez-Mariscal, Antonio P. Arenas-de Larriva, Patricia J. Peña-Orihuela, Ruth Blanco-Rojo, Javier Martinez-Botas, Jose D. Torres-Peña, Pablo Perez-Martinez, Jose M. Ordovas, Javier Delgado-Lista, Diego Gómez-Coronado and Jose Lopez-Miranda
    Citation: Cardiovascular Diabetology 2021 20:72
    Content type: Original investigation Published on:

    The Correction to this article has been published in Cardiovascular Diabetology 2021 20:79

  44. Diabetes mellitus is a common comorbidity of atrial fibrillation (AF), which can complicate the management of AF. The pharmacology of oral anticoagulants (OACs) have been implicated in pathogenesis of diabetes...

    Authors: Ching-Lung Cheung, Chor-Wing Sing, Wallis C. Y. Lau, Gloria H. Y. Li, Gregory Y. H. Lip, Kathryn C. B. Tan, Bernard M. Y. Cheung, Esther W. Y. Chan and Ian C. K. Wong
    Citation: Cardiovascular Diabetology 2021 20:71
    Content type: Original investigation Published on:

  45. The prevalence of hypertension and obesity has increased significantly in recent decades. Hypertension and obesity often coexist, and both are associated with increased cardiovascular mortality. Obese hyperten...

    Authors: Yahya M. Naguib, Rehab M. Samaka, Mohamed S. Rizk, Omnia Ameen and Shaimaa M. Motawea
    Citation: Cardiovascular Diabetology 2021 20:70
    Content type: Original investigation Published on:

  46. During COVID-19 pandemic, elective invasive cardiac procedures (ICP) have been frequently cancelled or postponed. Consequences may be more evident in patients with diabetes.

    Authors: Raúl Moreno, José-Luis Díez, José-Antonio Diarte, Pablo Salinas, José María de la Torre Hernández, Juan F. Andres-Cordón, Ramiro Trillo, Juan Alonso Briales, Ignacio Amat-Santos, Rafael Romaguera, José-Francisco Díaz, Beatriz Vaquerizo, Soledad Ojeda, Ignacio Cruz-González, Daniel Morena-Salas, Armando Pérez de Prado…
    Citation: Cardiovascular Diabetology 2021 20:69
    Content type: Original investigation Published on:

  47. Adiposity is a major component of the metabolic syndrome (MetS), low muscle strength has also been identified as a risk factor for MetS and for cardiovascular disease. We describe the prevalence of MetS and ev...

    Authors: Jose P. Lopez-Lopez, Daniel D. Cohen, Daniela Ney-Salazar, Daniel Martinez, Johanna Otero, Diego Gomez-Arbelaez, Paul A. Camacho, Gregorio Sanchez-Vallejo, Edgar Arcos, Claudia Narvaez, Henry Garcia, Maritza Perez, Dora I. Molina, Carlos Cure, Aristides Sotomayor, Álvaro Rico…
    Citation: Cardiovascular Diabetology 2021 20:68
    Content type: Original investigation Published on:

  48. Major prospective randomized clinical safety trials have demonstrated beneficial effects of treatment with glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium–glucose co-transporter-2 inhibitors (...

    Authors: Moa Lugner, Naveed Sattar, Mervete Miftaraj, Jan Ekelund, Stefan Franzén, Ann-Marie Svensson and Björn Eliasson
    Citation: Cardiovascular Diabetology 2021 20:67
    Content type: Original investigation Published on:

  49. Given the rising prevalence of dysglycemia and disparities in heart failure (HF) burden, we determined race- and sex-specific lifetime risk of HF across the spectrum of fasting plasma glucose (FPG).

    Authors: Arjun Sinha, Hongyan Ning, Faraz S. Ahmad, Michael P. Bancks, Mercedes R. Carnethon, Matthew J. O’Brien, Norrina B. Allen, John T. Wilkins, Donald M. Lloyd-Jones and Sadiya S. Khan
    Citation: Cardiovascular Diabetology 2021 20:66
    Content type: Original investigation Published on:

  50. Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduced cardiovascular risk in type 2 diabetes patients independently of glycemic control. Although angiotensin II (Ang II) and blood-derived microparticles ar...

    Authors: Sin-Hee Park, Eugenia Belcastro, Hira Hasan, Kensuke Matsushita, Benjamin Marchandot, Malak Abbas, Florence Toti, Cyril Auger, Laurence Jesel, Patrick Ohlmann, Olivier Morel and Valérie B. Schini-Kerth
    Citation: Cardiovascular Diabetology 2021 20:65
    Content type: Original investigation Published on:
journal logo

Cardiovascular Diabetology is affiliated with Sackler Faculty of Medicine, Tel-Aviv University

New Content Item

Submit manuscript

Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 8.5
    5-year Journal Impact Factor: 8.9
    Source Normalized Impact per Paper (SNIP): 1.855
    SCImago Journal Rank (SJR): 2.621

    Speed 2023
    Submission to first editorial decision (median days): 2
    Submission to acceptance (median days): 56

    Usage 2023
    Downloads: 2,523,778
    Altmetric mentions: 3,115

Cardiovascular Diabetology

ISSN: 1475-2840